SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Duke Kahanamoku

PatientDuke Kahanamoku
Date of birth1959-08-24
IdentifiersMRN HR-ML050-SYN; SSN (made up) 000-50-6847
Document date2026-09-28
AuthorKawika Lindgren-Morrison, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month review: repeat echocardiogram and the defibrillator decision. [S]

History of Present Illness

Mr. Kahanamoku returns two weeks after his annual wellness visit; at his wish, members of his ʻohana joined him for the defibrillator discussion. He completed all 36 sessions of cardiac rehabilitation in the summer, swam in the pool there for the last month, and now swims three mornings a week in calm water inside the reef with a friend; he has not surfed big waves. He has had no swelling, orthopnea, palpitations, lightheadedness or fainting. The planned increase of sacubitril-valsartan two weeks after his last review did not happen: the nurse called, but he put off the laboratory visit twice because of work, the call was not repeated, and he stayed on the starting dose. He takes every dose of his medicines. Today's echocardiogram shows the ejection fraction has risen from 30% to 38%. [S]

ElementDetail
RehabilitationAll 36 sessions completed
ActivitySwims three mornings a week in calm water with a companion
Missed stepSacubitril-valsartan increase and its laboratory check did not happen
EchocardiogramEjection fraction 38%, from 30%
KCCQ-1280, from 38 at intake

Review of Systems

SystemResultFinding
CardiovascularNegativeNo chest pain, palpitations, fainting or ankle swelling
RespiratoryNegativeBreathless only swimming hard against a current
NeurologicalNegativeNo lightheadedness

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Aspirin 81 mg delayed-release oral tablet, one tablet dailyOne tablet dailyOral route2021-06-21activeS
Atorvastatin 40 mg oral tablet, one tablet dailyOne tablet dailyOral route2021-06-21 to 2026-03-16completedS
Atorvastatin 80 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-16activeS
Metoprolol tartrate 25 mg oral tablet, one tablet twice dailyOne tablet twice dailyOral route2021-06-21 to 2026-03-30completedS
Lisinopril 10 mg oral tablet, one tablet dailyOne tablet dailyOral route2021-06-21 to 2026-03-30completedS
Furosemide 40 mg oral tablet, one tablet every morningOne tablet every morningOral route2026-03-16 to 2026-04-27completedS
Furosemide 20 mg oral tablet, one tablet every morningOne tablet every morningOral route2026-04-27activeS
Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet twice daily, first dose 36 hours after the last lisinoprilOne tablet twice dailyOral route2026-03-30 to 2026-09-28completedS
Sacubitril 49 mg / valsartan 51 mg oral tablet, one tablet twice dailyOne tablet twice dailyOral route2026-09-28activeS
Carvedilol 3.125 mg oral tablet, one tablet twice daily with food, starting the evening after the last metoprolol tartrateOne tablet twice daily with foodOral route2026-03-30 to 2026-04-13completedS
Carvedilol 6.25 mg oral tablet, one tablet twice daily with foodOne tablet twice daily with foodOral route2026-04-13 to 2026-04-27completedS
Carvedilol 12.5 mg oral tablet, one tablet twice daily with foodOne tablet twice daily with foodOral route2026-04-27activeS
Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating or drinkingOne tablet daily, with sick-day rulesOral route2026-03-30activeS
Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) dailyOne-half tablet dailyOral route2026-04-13activeS
Ferric carboxymaltose 750 mg (15 mL vial, 50 mg/mL) by intravenous infusion, two doses two weeks apartTwo infusions two weeks apartIntravenous route2026-03-30 to 2026-04-13completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-09-28Body height185cmS
2026-09-28Body weight92.8kgS
2026-09-28Body mass index (BMI) [Ratio]27.1kg/m2S
2026-09-28Systolic blood pressure106mm[Hg]S
2026-09-28Diastolic blood pressure66mm[Hg]S
2026-09-28Heart rate64/minS
2026-09-28Respiratory rate16/minS
2026-09-28Body temperature36.5CelS
2026-09-28Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-09-28Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma620pg/mLBelow 125 pg/mL makes heart failure unlikely outside the hospitalHighS
2026-09-28Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-09-28Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-09-28Creatinine [Mass/volume] in Serum or Plasma1.14mg/dL0.74-1.35 mg/dLNormalS
2026-09-28Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M70mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-09-28Glucose [Mass/volume] in Serum or Plasma95mg/dL70-99 mg/dLNormalS
2026-09-28Magnesium [Mass/volume] in Serum or Plasma2mg/dL1.6-2.6 mg/dLNormalS
2026-09-28Hemoglobin [Mass/volume] in Blood14.1g/dL13.2-16.6 g/dLNormalS
2026-09-28Ferritin [Mass/volume] in Serum or Plasma248ng/mLIn heart failure, below 100 ng/mL, or 100 to 299 with transferrin saturation below 20%, is iron deficiencyNormalS
2026-09-28Iron saturation [Mass Fraction] in Serum or Plasma27%20-50%NormalS
2026-09-28Left ventricular Ejection fraction38%50-70%LowS
2026-09-28Overall summary score [KCCQ-12]80{score}S

Physical Exam

Vital signs recorded on 2026-09-28; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 106/66, pulse 64; weight 92.8 kg
Orthostatic vital signsStanding at three minutes 104/64 mmHg without symptoms
NeckJugular venous pressure not raised
CardiovascularRegular rhythm; soft apical systolic murmur; no S3
RespiratoryClear
ExtremitiesNo edema

Problems

ProblemClinical statusVerificationCodeProvenance
Breathlessness on exertion for six weeks (paddling out, walking uphill, finishing his morning swim), with ankle swelling by evening and tiredness, five years after a heart attack; cause to be determinedresolvedconfirmed R06.09S — Synthetic presenting problem, resolved at the second visit when the echocardiogram and cardiology established heart failure with reduced ejection fraction.
Coronary artery disease with an old anterior myocardial infarction five years ago, treated with medicines; synthetic modern episode linked to the documented heart attack of 1952activeconfirmed I25.2S — Synthetic modern diagnosis; the 1952 heart attack remains D in the history.
Heart failure with reduced ejection fraction from ischemic cardiomyopathy (ejection fraction 30% with a thinned, akinetic anterior wall and apex), NYHA class III at diagnosisactiveconfirmed I50.22S — Synthetic modern diagnosis made at the second visit; no claim that he had heart failure in his lifetime.
Iron deficiency without anemia (ferritin 62 ng/mL, transferrin saturation 16%)activeconfirmed E61.1S — Synthetic finding at the heart failure workup.
Viral gastroenteritis for two days, with volume depletion, potassium 5.5 mmol/L and a rise in creatinine on sacubitril-valsartan, spironolactone, empagliflozin and furosemide; settled with sick-day rulesresolvedconfirmed A08.4S — Synthetic intercurrent problem at an unscheduled visit; it follows from his heart failure medicines and does not echo a documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure and heart rate (seated and standing)Every visitCompleted today106/66 mmHg, pulse 64; standing 104/64 without symptoms
ExaminationWeight, volume status (jugular venous pressure, edema, lungs) and NYHA classEvery visitCompleted today92.8 kg; jugular venous pressure not raised; no edema; NYHA I to II
LaboratoryMetabolic panel (sodium, potassium, creatinine and eGFR) and magnesiumOne to two weeks after a dose changeDeferredThe panel due one week after the planned sacubitril-valsartan increase was never drawn, because the increase itself did not happen: he put off the laboratory visit twice for work and the nurse's call was not repeated. No laboratory harm resulted (potassium 4.6, creatinine 1.14 today), but the ARNI stayed at the starting dose for about five months, which may have limited his recovery. Corrective action: laboratory tests drawn at the clinic on the day of each change or by the nurse at home, and nurse calls that continue until each step is done
LaboratoryMetabolic panel (sodium, potassium, creatinine and eGFR) and magnesiumEvery three to six months when stableCompleted todaySodium 138, potassium 4.6, creatinine 1.14 mg/dL (eGFR 70), magnesium 2.0
Medication safetyGuideline-directed medical therapy: ARNI, evidence-based beta-blocker, MRA and SGLT2 inhibitor, toward target dosesEvery two weeks during titrationCompleted todaySacubitril-valsartan raised to 49/51 mg today; panel in one to two weeks
ImagingEchocardiogramAt diagnosis; repeat after three to six months of optimized therapy for device decisions, or with unexplained changeCompleted todayAfter more than 90 days of therapy: ejection fraction 38% (from 30%), end-diastolic diameter 58 mm, mild mitral regurgitation
ExaminationPrimary-prevention ICD evaluation (and CRT if QRS is wide)After at least 90 days of optimized therapy, and at least 40 days after a myocardial infarctionNot indicatedEjection fraction 38%, above 35%; QRS 104 ms; no ICD or CRT now
LaboratoryNT-proBNPAt diagnosis; selectively for prognosis (not for titration)Completed today620 pg/mL, from 2,450, for prognosis
Medication safetyIron studies (ferritin, transferrin saturation) and intravenous ironAt diagnosis; after repletion and about yearlyCompleted todayFerritin 248 ng/mL, transferrin saturation 27%, hemoglobin 14.1 g/dL
SurveyKCCQ-12 heart failure health statusAt diagnosis, then every three to six monthsCompleted today80
LaboratoryLipid panelEvery three to twelve months when stableUp to dateLDL 62 mg/dL in the spring
SurveyDepression screen (PHQ-2, then PHQ-9 if positive)PeriodicallyUp to datePHQ-2 0 at the wellness visit
ReferralCardiac rehabilitation for heart failureWhen eligible: ejection fraction 35% or below, NYHA II to IV, six weeks of stable therapy and no procedure in six weeksCompleted todayAll 36 sessions completed in the summer; swimming in calm water with a companion
ExaminationVaccinations (pneumococcal, influenza, COVID-19, RSV)Yearly or per scheduleCompleted todayInfluenza, RSV and COVID-19 at the wellness visit; PCV20 in the spring; zoster dose 1 and Tdap today
Self-managementSelf-care: daily weights, sodium, sick-day rules and symptoms to reportEvery visitCompleted todayDaily weights; ocean plan followed; sick-day card kept in his wallet
Self-managementCulturally safe care: ʻohana involvement as he chooses; his own healing practicesEvery visitCompleted todayʻOhana included in the defibrillator discussion, as he asked at the wellness visit

Goal progress:

Immunizations given today: Recombinant zoster vaccine, dose 1 of 2; Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) [S]

Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction (2024); 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (2017); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026); Adult Immunization Schedule by Age (2026)

Follow-up: Zoster dose 1 and Tdap given today; second zoster dose in two to six months. Metabolic panel at the clinic in one to two weeks, with the nurse's call. Review in three months. Cardiology review in six months. Call 911 for chest pain, fainting or a racing heartbeat. [S]